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Anita Lerch  1,2,3,6, Cristian Koepfli3,4,6, Natalie E. Hofmann1,2, Johanna H. Kattenberg5,7, 
Anna Rosanas-Urgell5,7, Inoni Betuela5, Ivo Mueller3,4,8 & Ingrid Felger1,2
Longitudinal tracking of individual Plasmodium falciparum strains in multi-clonal infections is essential 
for investigating infection dynamics of malaria. The traditional genotyping techniques did not permit 
tracking changes in individual clone density during persistent natural infections. Amplicon deep 
sequencing (Amp-Seq) offers a tool to address this knowledge gap. The sensitivity of Amp-Seq for 
relative quantification of clones was investigated using three molecular markers, ama1-D2, ama1-D3, 
and cpmp. Amp-Seq and length-polymorphism based genotyping were compared for their performance 
in following minority clones in longitudinal samples from Papua New Guinea. Amp-Seq markers were 
superior to length-polymorphic marker msp2 in detecting minority clones (sensitivity Amp-Seq: 95%, 
msp2: 85%). Multiplicity of infection (MOI) by Amp-Seq was 2.32 versus 1.73 for msp2. The higher 
sensitivity had no effect on estimates of force of infection because missed minority clones were 
detected in preceding or succeeding bleeds. Individual clone densities were tracked longitudinally by 
Amp-Seq despite MOI > 1, thus providing an additional parameter for investigating malaria infection 
dynamics. Amp-Seq based genotyping of longitudinal samples improves detection of minority clones 
and estimates of MOI. Amp-Seq permits tracking of clone density over time to study clone competition 
or the dynamics of specific, i.e. resistance-associated genotypes.
Molecular-epidemiological parameters used to describe the infection dynamics of Plasmodium falciparum include 
the number of co-infecting parasite clones (multiplicity of infection, MOI), the rate at which different genotypes 
are acquired over time (molecular force of infection, molFOI) and duration of infection1. These measures are 
based on monitoring the presence or absence of clones in cross-sectional or longitudinal samples collected in 
regular intervals. In earlier studies, individual parasite clones in multi-clonal field samples were distinguished and 
tracked over time by genotyping the length-polymorphic marker merozoite surface protein 2 (msp2) by capillary 
electrophoresis-based fragment sizing (CE)2–4. Yet, msp2-CE genotyping has limited sensitivity for minority clone 
detection3,5,6. Alternative typing methods instead could perform better in detecting minority clones, but might 
impact measures of MOI and molFOI7,8. So far quantification of individual clones within multi-clonal infections 
was not feasible, as this would have required highly complex allele-specific quantitative PCR (qPCR).
SNP-based genotyping by deep amplicon sequencing (Amp-Seq) can detect low-abundant P. falciparum 
clones at ratios of 1:1000 in mixed infections7–9. Most importantly, genotyping by Amp-Seq also quantifies pre-
cisely the relative abundance of clones, as shown with artificial mixtures of clones9–11. From these ratios the abso-
lute density of each clone (i.e. a certain haplotype) within a multi-clone infection can be deduced if the total 
parasitaemia of the sample was established by qPCR11. When analysing consecutive samples from a given study 
participant, presence and fluctuations in density of clones can be tracked. We explore how longitudinal informa-
tion can be used to improve identification of minority clones with low densities around the detection limit.
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A previous study has estimated clonal density with Amp-Seq in multi-clone infections to estimate clear-
ance rates after antimalarial treatment11. We apply the same approach to track parasite clones longitudinally in 
untreated natural infections. In addition, we increase the resolution of genotyping by combining sequence infor-
mation from several markers into multi-locus haplotypes.
Methods
Study design. A subset of 153 archived P. falciparum genomic DNA samples from 33 children (mean 4.3 
samples [min: 2, max: 11]) aged 1–5 years were available from a cohort study described earlier12 with blood 
sampling over 40 weeks (first 12 weeks every fortnight, then monthly) in Papua New Guinea (PNG). The two 
conditions for selection of children were: ≥2/14 bleeds PCR positive, and MOI > 1 in at least one of the samples 
of each child. Ethical clearance was obtained from PNG Institute of Medical Research Institutional Review Board 
(IRB 07.20) and PNG Medical Advisory Committee (07.34). Informed written consent was obtained from all par-
ents or guardians prior to recruitment of each child. All experiments were performed in accordance with relevant 
guidelines and regulations.
Genotyping using length polymorphic marker msp2. Samples were genotyped using the classical P. 
falciparum marker msp2 according to published protocols13. Fluorescently labelled nested PCR products were 
sized by CE on an automated sequencer and analysed using GeneMarker software. Fragments were accepted if the 
following cut-off criteria were met: peak height >500 intensity units and >10% of the height of the majority peak. 
Electropherograms were inspected visually to exclude obvious stutter peaks. All DNA samples were genotyped in 
2 independent laboratories to assess reproducibility of clone detection and measures of MOI.
Marker selection for Amplicon deep sequencing. Amp-Seq was performed on three amplicons located 
in two different P. falciparum marker genes, namely PF3D7_0104100, “conserved Plasmodium membrane pro-
tein” (cpmp), and PF3D7_1133400, “apical membrane antigen 1” (ama1) whose genetic diversity has been studied 
in great detail7,14–16. Previously published primers were used for marker cpmp9. For ama1 two amplicons of 479 
and 516 bp were selected that span regions of maximum diversity, i.e. subdomains 2 and 3 of the ectodomain17. 
Primer sequences and exact amplicon positions are listed in Supplementary Tables S1 and S2.
Sequencing library preparation. Sequencing libraries were generated by three rounds of PCR, accord-
ing to previously published protocols9. After primary PCR, a 5′ linker sequence was added during nested PCR. 
Nested PCR products were subject to another PCR round with primers binding to the linker sequences and 
carrying Illumina sequence adapters plus an eight nucleotide long sample-specific molecular index to permit 
pooling of amplicons for sequencing and later de-multiplexing. The final sequence library was purified with 
NucleoMag beads. Sequencing was performed on an Illumina MiSeq platform in paired-end mode (2 × 250 bp) 
using Illumina MiSeq reagent kit v2 (500-cycles) together with Enterobacteria phage PhiX control (Illumina, 
PhiXControl v3).
Sequence read analysis and haplotype calling. Samples yielding a sequence coverage of <25 reads 
were excluded from the analysis. An overview of sequence read coverage for all Amp-Seq markers is given in 
Supplementary Table S3. Several pipelines to process Amp-Seq data have recently been published, including 
HaplotypR (https://github.com/lerch-a/HaplotypR.git) that was used for this study9,18–21. Haplotype calling is 
explained in full detail in an earlier publication9. In short: Low quality sequences were removed by trimming 
reads to a final size of 240 bp forward and 170 bp reverse for all amplicons. Index, linker and primer sequence 
(corresponding to ~50 bp) were trimmed off from forward and reverse reads. As the reference sequence, P. fal-
ciparum strain 3D7 was used (PlasmoDB release 3422). The term genotype refers to a single nucleotide poly-
morphism (SNP), whereas a haplotype was defined as a sequence variant of an entire amplicon. Calling a SNP 
required a >50% frequency of the total reads in at least two independent samples. Haplotypes containing inser-
tions or deletions (indels) were filtered out, as well as haplotypes resulting from chimeric reads or singleton reads. 
The number of reads of a given haplotype over all remaining reads of the same marker within a sample is denoted 
by the term “within-host haplotype frequency”. Cut-off criteria for haplotype calling were as follows: a minimum 
of 3 reads coverage per haplotype, a within-host haplotype frequency ≥0.1% and an occurrence of this haplotype 
in ≥2 samples over the entire data set including technical replicates. The chosen cut-off criteria where studied in 
great detail and discussed in an earlier publication9.
Multi-locus haplotype inference in longitudinal samples. Amp-Seq quantifies the frequency of each 
haplotype within a sample. This permits the inference of multi-locus haplotypes, an approach also used earlier by 
software DEploid23. In this study a semi-automated procedure was applied for multi-locus haplotype inference 
that utilized longitudinal sample information to solve complex mixtures. A multi-locus haplotype was deduced 
iteratively and separately for each sample. In the first round, the multi-locus haplotype of the dominant clone of 
a sample was inferred by selecting each marker’s dominant haplotype (>54% within-host haplotype frequency, 
i.e. 50% + 3.8% standard deviation in within-host haplotype frequency between replicates). After each round, the 
identified dominant haplotype was ignored and in the following round the dominant haplotype was identified 
among the remaining reads. If several haplotypes occurred in a sample at similar frequencies, it may be impossible 
to identify the dominant haplotype. Nevertheless, in many cases this could be resolved by analysing the change in 
within-host haplotype frequency between the observed and preceding or succeeding sample of the same host. An 
example of our approach to multi-locus haplotype inference is shown in detail in Supplementary Text.
The final step of multi-locus haplotype inference addressed the problem of clones from a multiple infection 
that share by chance the same allele of one of the markers. As a consequence, the within-host frequency of a 
shared haplotype amounts to the sum of two or more independent clones carrying the same allele. In such cases 
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multi-locus haplotypes were inferred by assigning the shared alleles to those haplotypes that summed up to the 
same proportion in the other two markers. Samples for which the multi-locus haplotype could not be established 
by this approach were considered unresolvable (Supplementary Table S4).
Reproducibility, sensitivity and false discovery rate. Samples were analysed in duplicate with 
Amp-Seq markers and msp2-CE. Performing duplicates permitted to identify and exclude false-positive hap-
lotypes and thus prevented erroneous over-estimation of MOI. Each haplotype was classified into one of four 
groups (example see Supplementary Fig. S1): (1) True-positive (TP) haplotype, i.e. it passed the haplotype calling 
cut-off in both replicates or in one replicate plus in the preceding or succeeding bleed; (2) False-positive (FP) 
haplotype, i.e. it passed the haplotype calling cut-off in only one replicate and was not detected in any of the 
preceding or succeeding samples of that individual; (3) False-negative (FNi) haplotype, i.e. it was detected in one 
or both replicates but did not pass the cut-off criteria at that occasion, whereas it was detected in the preceding or 
succeeding bleed as TP (at least once) or FN haplotype; (4) Background noise (all other cases).
Additionally, false-negative (FNii) haplotypes were imputed for samples in which no sequence read was 
detected. These false-negative haplotypes were imputed only when (a) the haplotype was detected in the preced-
ing as well as the succeeding bleed as a true-positive. Presence in only one of preceding or succeeding sample was 
not considered sufficient evidence for assuming a case of missed detection. For the Amp-Seq markers but not 
msp2-CE, false-negative haplotypes were also imputed when (b) data for the other two markers was present and 
the corresponding multi-locus haplotype was established in the preceding or succeeding sample.
The sensitivity to detect parasite clones was estimated based on selected individuals who had not received 
antimalarial treatment during the timespan analysed and harboured at least one haplotype that was detected at 3 
consecutive bleeds. Sensitivity was defined as the true positive rate of a genotyping method and was calculated as 
TP/(TP + FN). The risk to falsely assign a haplotype not present in the sample was measured as the “false discov-
ery rate” (FDR), calculated as FP/(TP + FP). This rate represents the extent of false haplotype calls of a genotyping 
method.
The reproducibility of clone detection in technical replicates (comprising all experiential procedures from 
PCR to sequence run) was calculated as 
+
n
n n
2
2
2
1 2
, where n1 is the number of haplotypes detected in a single replicate 
and n2 the number of haplotypes detected in both replicates24. Only TP haplotypes were used to estimate 
reproducibility.
Epidemiological parameters: clone density, diversity, MOI and FOI. The density of a parasite clone 
was calculated by multiplying within-host haplotype frequency by parasitaemia (measured by qPCR). As late P. 
falciparum stages are absent from peripheral blood owing to sequestration, it was assumed that all detected clones 
were ring or early trophozoite stages, which each possess a single haploid genome. Thus, genome density corre-
lates with clone density. Clone density is expressed as copies of target gene per microliter, quantified by qPCR tar-
geting the 18S rRNA gene of P. falciparum25. The technical detection limit of qPCR was 0.4 copies/μl whole blood.
Based on true positive haplotypes, the expected heterozygosity (He) and mean MOI were determined from 
baseline (or first bleed available) samples for each marker as described earlier9. He was also estimated for com-
bined markers in samples that had a resolvable multi-locus haplotype and that were separated by a treatment plus 
≥2 consecutive P. falciparum negative samples from the same child.
molFOI was estimated on longitudinal sets of sample that had a complete set of replicates for all markers. 
Haplotypes were counted as new infection if a haplotype was (i) not present in the baseline sample but in a 
subsequent sample, (ii) not detected at ≥2 consecutive preceding bleeds or (iii) not detected after antimalarial 
treatment plus after at least one negative sample. Time at risk was calculated as the timespan between baseline and 
last sampling, minus 14 days for each antimalarial treatment (to account for the prophylactic effect of treatment).
An overview of sample selection criteria applied for different types of analyses is listed in Supplementary 
Table S5.
Results
Genetic diversity of markers. The discriminatory power of Amp-Seq markers cpmp, ama1-D2 and 
ama1-D3, as well as length-polymorphic marker msp2-CE was estimated in 33 baseline samples (Supplementary 
Table S5). The resolution was highest for amplicon marker cpmp (He = 0.961) that distinguished 30 haplotypes 
and yielded a mean MOI = 2.45 (Table 1, MOI distribution by marker in Supplementary Fig. S2). The second-best 
Marker He Mean MOI Number of clonesa Number of haplotypes Number of SNPsb
msp2 CE 0.940 1.73c 57 20 n/a
cpmp 0.961 2.45c 81 30 48
ama1-D2 0.928 2.27c 75 15 17
ama1-D3 0.939 2.24c 74 22 11
Table 1. Genotyping results of 4 molecular markers analysed in 33 baseline field samples. He, expected 
heterozygosity. MOI, multiplicity of infection. aSum of all haplotypes in all samples. bWith respect to the 
reference sequence of P. falciparum strain 3D7. cPairwise comparison using two-sided paired t-test with 
adjusted p-value by Holm: p-value = 0.008 for ama1-D2 vs msp2-CE, p-value = 0.036 for ama1-D3 vs msp2-CE, 
and p-value = 0.005 for cpmp vs msp2-CE.
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resolution was obtained by marker msp2-CE (He = 0.940) that distinguished 20 haplotypes and measured a mean 
MOI = 1.73. Haplotype and SNP frequencies of Amp-Seq markers are shown in Fig. 1 and Supplementary Fig. S2.
Discriminatory power can be increased by combining multiple markers. Inference of multi-locus haplotypes 
was not possible for all baseline samples. Instead, 47 independent samples were analysed that had fully established 
multi-locus haplotypes (Supplementary Table S5). These 47 samples comprised 67 fully established multi-locus 
haplotypes. Combining marker cpmp with either of the two ama1 fragments yielded very high diversity (54 
and 56 haplotypes, He = 0.992 and 0.994 for cpmp/ama1-D2 and cpmp/ama1-D3) (Table 2 and Supplementary 
Fig. S3). Combining all 3 markers did not increase discriminatory power any further.
Using longitudinal genotyping data to increase detectability of clones. Imperfect detectability 
of parasite clones has been described previously in longitudinal genotyping studies1,26–28. Data from replicates 
and longitudinal samples can be used to make assumptions on missed clones. This permits imputing of missed 
haplotypes and thus improves the tracking of clonal infections within an individual over time. Two types of 
false-negative haplotypes were distinguished: (FNi) haplotypes that were detected below the cut-off and (FNii) 
haplotypes that were not detected but imputed (Supplementary Table S6). Supplementary Fig. S4 shows an exam-
ple of these different types of missed haplotypes for all Amp-Seq markers.
The sensitivity to detect parasite clones was estimated for each genotyping marker by enumerating 
false-negative haplotypes. Sensitivity was higher for the Amp-Seq markers than for msp2-CE (in decreasing order 
96.5%, 95.0%, 93.9% and 85.1% for ama1-D2, cpmp, ama1-D3 and msp2-CE) (Table 3). For ≥57% of the iden-
tified false-negative haplotypes, reads were detected but fell below cut-off criteria (category (i) above). If such 
haplotypes were counted as positives by relaxing the cut-off criteria, sensitivity would increase to 99.1%, 97.5% 
and 97.4% for Amp-Seq markers ama1-D2, cpmp and ama1-D3 (Table 3). Using the standard cut-off criteria, the 
false discovery rate of haplotypes for Amp-Seq markers was in the range of 0.9–4.2% (Table 3).
Reproducibility to detect parasite clones in technical replicates was greater for Amp-Seq markers than 
for marker msp2-CE (0.94, 0.93, 0.92 and 0.89 for ama1-D3, ama1-D2, cpmp and msp2-CE) (Supplementary 
Figure 1. Frequency of individual SNPs and haplotypes of three markers in 33 baseline samples from PNG. 
Non-reference allelic frequency (Non-Ref AF) of each SNP (left) and frequency of haplotypes in these baseline 
samples (right). n, number of observations per haplotype shown for 2 most prevalent haplotypes. Total number 
of different haplotypes: 30 for cpmp, 15 for ama1-D2 and 22 for ama1-D3. (Frequency of haplotypes for markers 
msp2-CE given in Supplementary Fig. S2).
Marker He Number of Haplotypes Mean MOI
cpmp 0.948 25 1.43
ama1-D2 0.925 16 1.30
ama1-D3 0.936 21 1.30
cpmp + ama1-D2 0.992 54 1.43
cpmp + ama1-D3 0.994 56 1.43
cpmp + ama1-D2 + ama1-D3 0.994 56 1.43
Table 2. Genotyping results of 3 molecular markers analysed in 47 independent field samples with 67 different 
clones. He, expected heterozygosity.
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Table S7). Reproducibility decreased either with decreasing clone density, decreasing within-host haplotype 
frequency, or decreasing sequence coverage (Supplementary Table S8 and Fig. S5)9. Differences in estimates of 
within-host haplotype frequency between replicates were very small: The median difference was 0.70%, 0.54% 
and 0.38% for cpmp, ama1-D3 and ama1-D2 (Supplementary Fig. S6).
Determination of molFOI by different molecular markers and methods. A higher sensitivity of the 
genotyping method does not necessary impact molFOI, i.e. new clones/year, because a missed minority clone 
could be detected at one of the successive bleeds. We investigated the number of new infections acquired during 
40 weeks follow-up in 27 children from whom a complete data set was available (on average 4.3 samples per child 
[min: 2, max: 7]) (Supplementary Figs S7–S39). Mean molFOI was 2.7, 2.7, 2.3 and 2.2 new infections per year 
for markers ama1-D3, cpmp, msp2-CE and ama1-D2 (negative binomial regression p-value for comparison of 
msp2-CE to ama1-D3, cpmp and ama1-D2: 0.596, 0.649 and 0.877) (Supplementary Fig. S40). Thus, no substan-
tial difference in mean molFOI was found for the different molecular markers and different genotyping methods. 
Mean molFOI of multi-locus haplotypes could not be calculated because multi-locus haplotype inference was not 
possible for all consecutive samples of each child (Supplementary Table S4).
Quantitative dynamics of multiple infecting P. falciparum clones. Densities of individual clones 
was calculated from the total parasitaemia by qPCR and the within-host haplotype frequency. Examples of indi-
vidual clone density dynamics in children with multi-clone infections are shown for three Amp-Seq markers 
(Fig. 2). The density of some clones remained constant over time, whereas other clones showed fluctuations in 
density over 3 orders of magnitude (Fig. 2A,B). In some children the dominant clone remains dominant over 
the observation period (Fig. 2A), whereas in others switch-over between minority clone and dominant clone 
was observed (Fig. 2B). In highly complex field samples some clones might share the same haplotype of a given 
marker (Fig. 2C). Such clones can only be differentiated and quantified if multiple markers are typed and at least 
one of the markers is not shared between concurrent clones.
After artemisinin combination therapy, some of the parasite clones from multi-clone infections were cleared 
14 days after antimalarial treatment, whereas others were still detectable (Fig. 2A–C). These persisting clones had 
decreased clone densities (<21 copies/μl) and likely represent remaining late gametocyte stages of cleared asex-
ual infections29. Some new infections following antimalarial treatment (artesunate-primaquine) showed a rapid 
increase in clone density within the first 14 days after re-infection of a host, followed by a slow decrease in clone 
density until clearance (Fig. 2D), whereas in other infections clone density remained constant (Fig. 2C).
Discussion
While MOI and molFOI have been extensively described as epidemiological parameters, the ratio and density of 
individual clones within complex infections has not yet been investigated in detail. This gap in knowledge was 
due to shortfalls of traditional length-polymorphic markers, where the length of a fragment greatly influences the 
amplification efficiency in multi-clone infections with fragments competing in PCR and a strong bias favouring 
smaller fragments5. As a result, multi-locus haplotypes could not be inferred from traditional genotyping data in a 
reliable way. Such inference is required, for example, for phylogenetic or population genetic studies. In these stud-
ies, multiple-clone infections were usually excluded or only the predominant haplotype included30,31. With the 
possibility to establish multi-locus haplotypes from complex infections the discriminatory power will be greatly 
improved in future. This study explored the feasibility of multi-locus haplotype calling in complex infections and 
the usefulness of the Amp-Seq genotyping technique in longitudinal data.
Single Amp-Seq markers cpmp, ama1-D2, ama1-D3, and msp2-CE yielded similar resolution. Combining 
cpmp with either of the ama1 fragments increased further discriminatory power. The excellent performance of 
Amp-Seq marker cpmp had been demonstrated earlier9. Such increased resolution is of great practical value for 
PCR-correction in clinical drug efficacy trials, where new infections need to be reliably distinguished from those 
present in an individual earlier6,32,33. Discriminatory power may be increased even further by replacing one of the 
Marker
TP FN FP Sensitivity FDR Detected Haplotypesa
n ni niia niib n TP/(TP + FNi+iiab) FP/(TP + FP) (TP + FNi)/(TP + FNi+iiab)
msp2-CE 86 10 5 n/ab n/ac 0.851 ± 0.101d n/ac 0.950 ± 0.061d
cpmp 115 4 2 1 5 0.943 ± 0.066 0.042 ± 0.057 0.975 ± 0.044
ama1-D2 109 3 0 1 1 0.965 ± 0.052 0.009 ± 0.027 0.991 ± 0.026
ama1-D3 108 4 2 1 3 0.939 ± 0.068 0.027 ± 0.046 0.974 ± 0.045
Table 3. Sensitivity and false discovery rate (FDR) of the genotyping method. Sensitivity and FDR including 
95% confidence interval was estimated based on persistent clones in 48 longitudinal samples from 12 
individuals. Detectability of minority clone can be increased by including missed persistent haplotypes detected 
below the cut-off criteria. TP, true-positive haplotypes. FNi, false-negative haplotypes detected, but below cut-
off criteria. FNiiab, false-negative haplotypes with no read detected. aDetected true-positive and false-negative 
haplotypes. bNot imputed for msp2-CE as multi-locus haplotypes cannot be established. cLength-polymorphic 
data generated in different laboratories do not provide replicates suited for determination of false-positive 
haplotype calls and estimation of FDR. dWithout haplotypes, that were imputed based on multi-locus 
haplotypes at the beginning or end of an infection.
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two ama1 fragments with another highly discriminatory marker that has no linkage to either Amp-Seq marker 
cpmp nor ama1.
Reproducibility of true-positive haplotype calls was measured based on two technical replicates. By definition, 
a true haplotype must occur in all replicates except for three cases: (1) imperfect detectability of low-density clones, 
where scarce template may, by chance, lead to occasional absence of the PCR template in one of the replicates, (2) 
template competition impeding minority clones, whereby templates of a minority clone, present at very low abun-
dance, are outcompeted by dominant clones, and (3), insufficient sequence depth to detect the minority clone in 
one replicate. It is essential to differentiate between false-positive haplotype calls (caused by cross-contamination, 
or amplification and sequencing errors9,11) and imperfect detection. This was achieved by considering preceding or 
succeeding bleeds of an individual. This approach was applied for those cases only where a haplotype was missed 
in one of the replicates. In our data set, all missing haplotype calls of replicates could be assigned to one of the three 
causes: imperfect detection, template competition or insufficient sequence depth.
Genotyping longitudinal samples in duplicates enabled also an evidence-based approach to identify 
false-negative haplotypes. This permitted the estimation of each marker’s sensitivity to detect minority clones. 
The estimated sensitivities of minority clone detection should serve primarily for a comparison of different geno-
typing methods, as the sample’s true haplotype composition remain uncertain. Amp-Seq genotyping with mark-
ers ama1-D2, ama1-D3 and cpmp missed fewer clones compared to msp2-CE genotyping (Amp-Seq in average 
5.4% versus 14.9% msp2-CE). This difference is likely due to less stringent cut-off criteria for Amp-Seq compared 
to msp2-CE genotyping. Minority clone detection by msp2-CE is limited by peak calling cut-off criteria, which 
are usually a fixed minimal signal intensity plus a minimum peak height of 10% (used in our study) or more of 
the dominant peak. Minority clones with an abundance of <10% of all amplified fragments will not pass these 
criteria. An increase of msp2-CE sensitivity would require a lower cut-off, which would lead to more false positive 
signals from either stutter peaks or background noise. In contrast, Amp-Seq allows the removal of PCR artefacts 
before haplotype calling and thus can support a much lower cut-off of <1%9.
In cohort studies where Amp-Seq genotyping is performed in successive follow up samples of the same 
patient, an even more relaxed definition of Amp-Seq cut-off criteria would be justifiable. In this scenario, the 
same evidence-based strategy of using successive samples can be used to recover minority haplotypes that were 
detected with read counts below the haplotype calling cut-offs. If recovery would be performed in this study, 
≥57% of all false-negative haplotypes would be identified. Such recovery would increase detectability of parasite 
clones by Amp-Seq to >97%. In addition, multi-locus haplotypes could provide additional evidence for accurate 
recovery.
The higher sensitivity of Amp-Seq to detect minority clones compared to msp2-CE substantially increased 
MOI, but did not affect mean molFOI. Any estimation of molFOI needs to account for temporary absence of clones 
from the peripheral blood caused by sequestration1,26–28. A clone that is temporarily undetectable owing to den-
sity fluctuations is likely observed at either the preceding or succeeding bleed. Therefore, a clone is usually only 
counted as new infection if it was not detected in ≥2 consecutive blood samples. As a consequence, a clone 
missed at a single bleed will not necessarily lead to a decrease of molFOI.
Figure 2. Dynamics of multi-clone infections in 4 children. Multi-marker haplotypes could be generated 
in panels A, B and C. Inference of multi-locus haplotypes was not possible for the child in panel D; here 
the dynamics of individual clones tracked by marker ama1-D2 are shown. Each colour represents a clone. 
Individual markers are represented by different shapes: cpmp (diamonds), ama1-D2 (circles) and ama1-D3 
(squares). Solid line connecting multi-locus haplotypes represents their median frequency. Grey dotted vertical 
lines represent sampling dates. Red dashed lines represent day of artemisinin combination therapy. Red dash-
dotted line represents end of radical cure (artesunate-primaquine) at baseline.
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A clone that was intermittently missed at one bleed by msp2-CE was always detected by Amp-Seq. This 
observation supports the practice in earlier publications where intermittently missed clones were imputed27,28. 
Counting a recurrent haplotype as new infection after a single negative bleed would lead to an overestimation 
of molFOI1,3,26–28. The statistical power of the current study was limited and a larger sample size is needed to fully 
explore the effect of the typing method used on estimates of MOI or molFOI.
A major advantage of Amp-Seq over msp2-CE is that the density of an individual clone in multi-clone infec-
tions can be calculated. Quantifying the density of individual parasite clones over time permits the studying of 
dynamics, and thus fitness, of parasite clones exposed to within-host competition34. For example, the relative 
densities of new infections can be compared to clones already persisting in a host, and their densities in respect to 
extrinsic factors or clinical symptoms can be investigated.
For infections with high multiplicity (MOI ≥ 3), inference of multi-locus haplotypes remains challenging 
(example in Supplementary Fig. S41). Inference is straightforward if a haplotype occurs at a distinctive abundance 
in any of the longitudinal samples (Supplementary Table S4). In contrast, if haplotypes are equally abundant in 
one sample and also remain so over several time points, the multi-locus haplotype cannot be inferred. Inference 
also is impossible for complex patterns with shared haplotypes, i.e. if a haplotype has a high population frequency 
and therefore is present in 2 or more clones of a blood sample. Shared haplotypes may even lead to inference of 
wrong multi-locus haplotypes, e.g. when three clones were present at an equal within-host frequency, though 
only two haplotypes were measured at each locus. However, the risk of erroneous multi-locus haplotype inference 
decreases if more than 2 unlinked markers are used, as the likelihood of shared multi-locus haplotypes decreases 
with increasing number of loci. In the present study, multi-locus haplotypes up to MOI = 3 were inferred. For 
multiplicity >3 and for resolving complex patterns of shared haplotypes, additional longitudinal samples could be 
analysed simultaneously, for example by incorporating the within-host haplotype frequencies of all consecutive 
samples of an individual into DEploid software23.
Conclusion
Amplicon sequencing improves clone detectability compared to msp2-CE owing to its greater sensitivity for 
detection of minority clones. Our results confirm earlier assumptions on clone persistence with intermittent 
missed observation. This validates the imputation of false negatives to correct for imperfect detection of clones, 
a strategy also used in previous studies on clone dynamics. Using multi-locus haplotypes for genotyping per-
mitted to identify robustly individual clones and improved differentiation between new and recurring clones. 
Construction of multi-locus haplotypes are of great value to compensate the effects of highly abundant haplotypes 
in the population. The option to quantify individual clones enables new approaches to investigate effects of para-
site fitness or superinfection in multi-clone infections.
Data Availability
The datasets generated and analysed during the current study are available in NCBI Sequence Read Archive 
repository under accession number SRX2704363 (https://www.ncbi.nlm.nih.gov/sra/SRX2704363). The source 
code for software HaplotypR is available at https://github.com/lerch-a/HaplotypR.
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